Literature DB >> 18400490

Aldosterone and the vascular system.

Victoria Cachofeiro1, Maria Miana, Natalia de Las Heras, Beatriz Martín-Fernández, Sandra Ballesteros, Jesús Fernández-Tresguerres, Vicente Lahera.   

Abstract

Aldosterone can act in different tissues exerting physiological and pathological effects. At the vascular level, aldosterone affects endothelial function since administration of aldosterone impaired endothelium-dependent relaxations. In addition, the administration of mineralocorticoid receptor antagonists ameliorate relaxation to acetylcholine in models of both hypertension and atherosclerosis and in patients with heart failure. A reduction in nitric oxide levels seems to be the main mechanism underlying this effect due to a reduction in its production as well as an increase in its degradation by reactive oxygen species. Aldosterone is a pro-inflammatory factor that can participate in the vascular inflammatory process associated with different pathologies including hypertension through activation of the NFkappaB system, which mediates the vascular production of different cytokines. This mineralocorticoid also participates in the vascular remodeling observed in hypertensive rats since the administration of eplerenone improved the media-to-lumen ratio in these animals. This effect seems to be due to an increase in extracellular matrix. In summary, aldosterone through mineralocorticoid receptors can participate in the vascular damage associated with different pathologies including hypertension through its prooxidant, pro-inflammatory and profibrotic effects that triggered endothelial dysfunction, an inflammatory process and vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18400490     DOI: 10.1016/j.jsbmb.2008.03.005

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  20 in total

1.  Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Ping Tepper; Emma Barinas-Mitchell; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Clin Exp Hypertens       Date:  2011-10-18       Impact factor: 1.749

2.  Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment.

Authors:  Guido Zavatta; Guido Di Dalmazi; Carmine Pizzi; Giovanni Bracchetti; Cristina Mosconi; Caterina Balacchi; Uberto Pagotto; Valentina Vicennati
Journal:  Endocrine       Date:  2018-11-14       Impact factor: 3.633

3.  Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney.

Authors:  Danita Eatman; Mohammed F Layas; Mohamed A Bayorh
Journal:  Kidney Blood Press Res       Date:  2010-06-23       Impact factor: 2.687

4.  Effects of aldosterone and related steroids on LPS-induced increased expression of inducible NOS in rat aortic smooth muscle cells.

Authors:  V Godfrey; A L Martin; A D Struthers; G A Lyles
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

5.  Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.

Authors:  C A Carvajal; A A Herrada; C R Castillo; F J Contreras; C B Stehr; L M Mosso; A M Kalergis; C E Fardella
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

6.  Rapid aldosterone signaling and vascular reactivity: relax or don't do it.

Authors:  Jane A Leopold
Journal:  J Cardiovasc Pharmacol       Date:  2009-12       Impact factor: 3.105

7.  Pediatric reference intervals for aldosterone, 17alpha-hydroxyprogesterone, dehydroepiandrosterone, testosterone and 25-hydroxy vitamin D3 using tandem mass spectrometry.

Authors:  Offie P Soldin; Hirsh Sharma; Lucas Husted; Steven J Soldin
Journal:  Clin Biochem       Date:  2009-02-06       Impact factor: 3.281

Review 8.  Mineralocorticoid receptor antagonists and endothelial function.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Curr Opin Investig Drugs       Date:  2008-09

9.  Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor.

Authors:  Jyotsna B Pippal; Yizhou Yao; Fraser M Rogerson; Peter J Fuller
Journal:  Mol Endocrinol       Date:  2009-06-18

10.  Vascular compliance in women with polycystic ovary syndrome treated with spironolactone.

Authors:  Ozgul Muneyyirci-Delale; Sherilyne Co; Nathaniel Winer
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-09-14       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.